Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/03/21/2850106/0/en/InflaRx-Reports-Full-Year-2023-Results-and-Announces-INF904-Development-Plans.html
https://www.globenewswire.com/news-release/2024/03/19/2848459/0/en/InflaRx-to-Announce-Development-Plans-for-INF904-and-2023-Financial-Results-on-March-21-2024.html
https://www.globenewswire.com//news-release/2024/01/25/2816626/0/en/InflaRx-Announces-Initiation-of-its-Commitment-Program-for-GOHIBIC-vilobelimab-to-Help-Broaden-Access-for-Eligible-Patients.html
https://www.globenewswire.com//news-release/2024/01/04/2803830/0/en/InflaRx-Announces-Positive-Topline-Results-from-the-Multiple-Ascending-Dose-MAD-Phase-I-Study-with-C5aR-Inhibitor-INF904.html
https://www.globenewswire.com//news-release/2023/11/06/2773976/0/en/InflaRx-Announces-First-Patient-Dosed-in-Phase-III-Trial-with-Vilobelimab-in-Pyoderma-Gangrenosum.html
https://www.globenewswire.com//news-release/2023/11/01/2771018/0/en/InflaRx-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com//news-release/2023/09/11/2740655/0/en/InflaRx-Announces-Positive-Topline-Results-from-the-Single-Ascending-Dose-SAD-Phase-I-Study-with-C5aR-Inhibitor-INF904.html
https://www.globenewswire.com//news-release/2023/08/30/2734224/0/en/InflaRx-s-Marketing-Authorization-Application-MAA-for-Vilobelimab-for-Treatment-of-Critically-Ill-COVID-19-Patients-under-Review-by-European-Medicines-Agency-EMA.html
https://www.globenewswire.com/news-release/2023/08/10/2722561/0/en/InflaRx-Reports-Second-Quarter-2023-Financial-Results-Operating-Update.html
https://www.globenewswire.com/news-release/2023/06/28/2696083/0/en/InflaRx-Appoints-Dr-Camilla-Chong-as-Chief-Medical-Officer.html